Osimertinib In EGFR Mutant Lung Cancer

"Patients who fulfill eligibility criteria will be entered into the trial to receive Osimertinib.~After the screening procedures confirm participation in the research study:~* Osimertinib: Oral, Daily 28 day cycle.~* Radiographic assessment: every 2 cycles for first 6 months and then every 3 cycles until disease progression.~* Tumor biopsy between C4 and C8 and at disease progression"